Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 8/20 | 0.71 |
| ▸ | RHOC | P08134 | 1/20 | 0.60 |
| ▸ | RHOA | P61586 | 1/20 | 0.60 |
| ▸ | TACR3 | P29371 | 1/20 | 0.54 |
| ▸ | DAGLA | Q9Y4D2 | 7/20 | 0.53 |
| ▸ | ABHD6 | Q9BV23 | 5/20 | 0.53 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8925154 | 0.94 | TACR1 (0.64) | TACR1RHOCRHOATACR3DAGLA | |
| SCHEMBL4438135 | 0.89 | RHOC (0.73) | TACR1RHOCRHOA | |
| SCHEMBL9113036 | 0.84 | TACR1 (0.78) | TACR1RHOCRHOATACR3 | |
| SCHEMBL9112230 | 0.84 | TACR1 (0.78) | TACR1RHOCRHOATACR3 | |
| SCHEMBL7459083 | 0.83 | TACR1 (1.00) | TACR1RHOCRHOATACR3 | |
| SCHEMBL13818185 | 0.83 | TACR1 (0.77) | TACR1RHOCRHOATACR3 | |
| SCHEMBL8297226 | 0.83 | TACR1 (1.00) | TACR1RHOCRHOATACR3 | |
| SCHEMBL1534317 | 0.83 | RHOC (0.65) | TACR1RHOCRHOA | |
| SCHEMBL7643493 | 0.82 | TACR1 (0.81) | TACR1TACR3 | |
| SCHEMBL7643492 | 0.82 | TACR1 (0.81) | TACR1TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210015834-A1 | NK-1 ANTAGONISTS FOR USE IN THE TREATMENT OF OCULAR PAIN | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2021-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210015834-A1 | NK-1 ANTAGONISTS FOR USE IN THE TREATMENT OF OCULAR PAIN | OPRK1, OPRL1, KLKB1 | TACR1 18/4885RHOC 3731/4885RHOA 3619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.